Stocktoria
Cyclerion Therapeutics, Inc. CYCN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-03-18
Cyclerion Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.1M | $2.0M | $0 | $297,000 | $3.9M |
| R&D expense | $959,000 | $286,000 | $1.5M | $6.0M | $37.6M |
| Operating income | -$5.0M | -$3.6M | -$13.0M | -$18.5M | -$55.2M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$3.5M | -$3.1M | -$5.3M | -$44.1M | -$51.6M |
| EPS (diluted) | $-1.11 | $-1.21 | $-2.25 | $-20.28 | $-1.32 |
| Operating cash flow | -$3.3M | -$4.3M | -$21.2M | -$40.6M | -$36.5M |
| Free cash flow | — | — | — | -$40.6M | -$36.5M |
| Cash & equivalents | $3.2M | $3.2M | $7.6M | $13.4M | $54.0M |
| Total assets | $10.0M | $9.6M | $13.4M | $18.1M | $59.3M |
| Shareholders' equity | $9.1M | $8.8M | $11.3M | $10.5M | $48.2M |
Source: SEC EDGAR filings · CIK 0001755237 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.